The Myeloma Steering Committee (MYSC) addresses the design, prioritization, and evaluation of concepts for phase 2, 2/3, and 3 clinical trials in adult myeloma. Committee activities help foster collaboration between groups and institutions engaged in conducting trials. The MYSC's membership comprises NCTN group representatives, NCI-funded consortia representatives, community oncologists, Specialized Programs of Research Excellence (SPORE) representatives, biostatisticians, patient advocates, subject matter experts, and NCI staff.
Co-Chairs
Suzanne Lentzsch, M.D.
Columbia University
Sagar Lonial, M.D.
Emory University
Members
Sikander Ailawadhi, M.D.
Mayo Clinic
Leslie Ballas, M.D.
Cedars-Sinai Medical Center
Ajai Chari, M.D.
University of California, San Francisco
Cynthia Chmielewski
Patient Advocate
Adam D. Cohen, M.D.
University of Pennsylvania
Angela Dispenzieri, M.D.
Mayo Clinic
Boris Freidlin, Ph.D.
National Cancer Institute
Susan Geyer, Ph.D.
Mayo Clinic
Sergio Giralt, M.D.
Memorial Sloan Kettering Cancer Center
Michael Green, M.D.
Kaiser Permanente
Antje Hoering, Ph.D.
Cancer Research and Biostatistics
Christopher Kelsey, M.D.
Duke University
Richard Little, M.D.
National Cancer Institute
Teresa Miceli
Patient Advocate
Robert Orlowski, M.D., Ph.D.
University of Texas M.D. Anderson Cancer Center
S. Vincent Rajkumar, M.D.
Mayo Clinic
Anthony Reiman, M.D., SM
Saint John Regional Hospital
Preet Paul Singh, M.D.
Springfield Clinic
Edward Stadtmauer, M.D.
University of Pennsylvania
Howard Streicher, M.D.
National Cancer Institute
Suzanne Trudel, M.D.
University Health Network
Saad Usmani, M.D.
Memorial Sloan Kettering Cancer Center
Christopher Venner, M.D.
BC Cancer Agency
Peter Voorhees, M.D.
Wake Forest University
NCI CCCT Program Director
Elena Schwartz, Ph.D., M.S.
elena.schwartz@nih.gov